Recombinant Human JAM-A (C-6His)

Description

EnkiLife provides the Recombinant Human JAM-A (C-6His) protein,aslo know as Junctional Adhesion Molecule A,JAM-A,Junctional Adhesion Molecule 1,JAM-1,Platelet F11 Receptor,Platelet Adhesion Molecule 1,PAM-1,CD321,F11R,JAM1,JCAM, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Junctional Adhesion Molecule A is produced by our Mammalian expression system and the target gene encoding Ser28-Val238 is expressed with a 6His tag at the C-terminus.Accession:Q9Y624. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:23.89 KDa. Background:Junctional Adhesion Molecule A (JAM-A) is a single-pass type I membrane protein that belongs to the immunoglobulin superfamily. JAM-A contains 2 Ig-like V-type (immunoglobulin-like) domains and Interacts with the ninth PDZ domain. JAM-A is localized to the tight junctions of both epithelial and endothelial cells. JAM-A seems to be involved in epithelial tight junction formation. JAM-A appears early in primordial forms of cell junctions and recruits PARD3. The association of the PARD6-PARD3 complex may prevent the interaction of PARD3 with JAM-A, thereby preventing tight junction assembly. JAM-A plays a role in regulating monocyte transmigration involved in regulating integrity of the epithelial barrier. In the case of orthoreovirus infection, JAM-A serves as receptor for the virus.